What’s the current market cap for Edwards Lifesciences stock?

Edwards Lifesciences (EW) has a market cap of $50bn as of June 19, 2026.

What is the P/E ratio for Edwards Lifesciences stock?

The price to earnings (P/E) ratio for Edwards Lifesciences (EW) stock is 46.45 as of June 19, 2026.

Does Edwards Lifesciences stock pay dividends?

No, Edwards Lifesciences (EW) stock does not pay dividends to its shareholders as of June 19, 2026.

When is the next Edwards Lifesciences dividend payment date?

Edwards Lifesciences (EW) stock does not pay dividends to its shareholders.

What is the beta indicator for Edwards Lifesciences?

Edwards Lifesciences (EW) has a beta rating of 0.87. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Edwards Lifesciences stock | $EW Share Price

About Edwards Lifesciences

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

Ticker

$EW

Sector

Health

Primary listing

NYSE

Employees

16,000

Headquarters

Irvine, United States

Website

www.edwards.com

EW Metrics

BasicAdvanced

$50bn

46.45

$1.88

0.87

-

What the Analysts think about EW

Analyst ratings (Buy, Hold, Sell) for Edwards Lifesciences stock.

Bulls say / Bears say

Edwards Lifesciences beat Wall Street first-quarter estimates on April 23, 2026, driven by robust demand for its artificial transcatheter valves, with TAVR sales rising 14.4% to $1.2 billion and shares up over 4% in extended trading. (Reuters).

The FDA approved Edwards’ SAPIEN M3 mitral valve replacement system—the first transseptal transcatheter therapy for mitral regurgitation—broadening its structural heart portfolio and expanding its addressable US patient base. (Reuters).

Edwards noted in its Q1 2026 earnings call that its PASCAL repair system pipeline remains on track, with next-generation technology expected in Q4 2026 for both mitral and tricuspid applications, positioning the company for continued TMTT segment growth. (Edwards Lifesciences Q1 transcript).

The FTC obtained a ruling in January 2026 blocking Edwards Lifesciences’ proposed acquisition of JenaValve, curbing its inorganic expansion into transcatheter aortic regurgitation therapies and limiting future M&A growth opportunities. (Reuters).

Edwards faces intensifying competition in its core TAVR market from rivals including Medtronic, Abbott, and Boston Scientific, which may erode its market share and pressure pricing dynamics. (Reuters).

Edwards reported that foreign exchange fluctuations reduced its Q1 2026 gross profit margin by roughly 30 basis points year-over-year, highlighting its vulnerability to currency volatility across its predominantly non-US revenue base. (MarketBeat).

Data summarised monthly by Lightyear AI. Last updated on 31 May 2026.

EW Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

EW Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

EW News

AllArticlesVideos

Edwards Lifesciences Stands Out As US Agency Eyes Broader Access For Heart Valve Device

Benzinga·3 days ago

East West Announces $858,000 Non-Brokered Private Placement

Newsfile Corp·1 week ago

AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth

Schwab Network·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.